Lupin Receives US FDA Approval for Generic Alphagan P Ophthalmic Solution, 0.1%
Overview
Global pharma major Lupin Limited (Lupin) announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application for brimonidine tartrate ophthalmic solution, 0.1%, to market a generic equivalent of Alphagan P ophthalmic solution, 0.1%, of AbbVie Inc. This product will be manufactured at Lupin’s Pithampur facility in India.
Brimonidine Tartrate Ophthalmic Solution
Indication- Brimonidine tartrate ophthalmic solution, 0.1% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Annual sale- Brimonidine tartrate ophthalmic solution (Alphagan P) had an estimated annual sales of USD 178.5 million in the US (IQVIA MAT June 2024).
About Lupin Limited
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets.
Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!